MedPath

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumors Cancer
Interventions
Drug: ABBV-927
Drug: ABBV-181
Registration Number
NCT02988960
Lead Sponsor
AbbVie
Brief Summary

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
163
Inclusion Criteria
  • Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
  • Participants have adequate bone marrow, kidney and liver function.
  • Participants with a history of chronic heart failure or significant cardiovascular disease must have an echocardiogram or multigated acquisition scan indicating left ventricular ejection fraction greater than or equal to 45% within 28 days prior to the first dose of study drug.
  • Participants must have creatinine clearance greater than or equal to 50 mL/min as measured by 24-hour urine or estimated by the Cockcroft-Gault formula.
  • Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
  • Participants in all monotherapy arms must have an advanced solid tumor that has progressed on standard therapies known to provide clinical benefit or the participants are intolerant to such therapies.
  • Participants in all combination therapy arms must have recurrent or metastatic HNSCC or NSCLC and previously received platinum-based therapy and progressed either during or after anti-programmed death ligand 1 (PDL1)-based therapy. In addition, participants must have received only one prior immunotherapy.
  • The Sponsor may decide to limit the specific tumor types selected or treatment settings for specific arms based on evidence gathered.
Read More
Exclusion Criteria
  • Participant must not have an active or prior documented autoimmune disease in the last 2 years.
  • Participant must not have current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).
  • Participant must not have a history of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, previous clinical diagnosis of tuberculosis, inflammatory bowel disease, interstitial lung disease, or immune-mediated pneumonitis.
  • Participant must not have a history of clinically significant uncontrolled condition(s) including but not limited to the following: uncontrolled hypertension; symptomatic congestive heart failure; unstable angina pectoris or cardiac arrhythmia including atrial fibrillation.
  • Participant must not have a history of coagulopathy or a platelet disorder associated with significant clinical risk of thromboembolic event in the judgement of the investigator, or major thromboembolic event within 6 months prior to the first dose of study treatment.
  • Participant must not have a prior grade greater than or equal to 3 immune-mediated neurotoxicity or pneumonitis while receiving immunotherapy.
  • Participant must not have a known uncontrolled malignancy of the central nervous system.
  • Participants in all combination therapy arms must not have a history of exposure to an immunotherapy experiencing an immune-mediated adverse event that required permanent discontinuation of the immunotherapy.
  • Female participants must not be pregnant, breastfeeding or considering becoming pregnant during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
  • Male participants must not be considering fathering a child or donating sperm during the study or for at least 3 or 5 months (for monotherapy and combination therapy participants, respectively) after the last dose of study drug.
  • Participant is judged by the investigator to have evidence of hemolysis.
  • For Japan only, participants with a history of interstitial lung disease (pneumonitis) or current interstitial lung disease (pneumonitis).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Escalating Arm 1: ABBV-927ABBV-927Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
Expansion Arm B: ABBV-927+ABBV-181ABBV-181Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
Escalating Arm 4: ABBV-927+ABBV-181ABBV-927Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
Escalating Arm 5 (Japan): ABBV-927ABBV-927Participants with solid tumors will receive escalating intravenous (IV) doses of ABBV-927.
Escalating Arm 2: ABBV-927ABBV-927Participants with solid tumors will receive escalating intratumoral (IT) doses of ABBV-927.
Escalating Arm 4: ABBV-927+ABBV-181ABBV-181Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive escalating IT doses of ABBV-927 and IV doses of ABBV-181.
Escalating Arm 6 (Japan): ABBV-927+ABBV-181ABBV-181Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
Expansion Arm A: ABBV-927ABBV-927Additional participants with HNSCC or NSCLC will receive intravenous (IV) doses of ABBV-927.
Escalating Arm 3: ABBV-927+ABBV-181ABBV-927Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
Escalating Arm 3: ABBV-927+ABBV-181ABBV-181Participants with Non-Small Cell Lung Cancer (NSCLC) will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
Expansion Arm B: ABBV-927+ABBV-181ABBV-927Additional participants with HNSCC will receive IT doses of ABBV-927 and IV doses of ABBV-181.
Escalating Arm 6 (Japan): ABBV-927+ABBV-181ABBV-927Participants with solid tumors will receive escalating IV doses of ABBV-927 and IV doses of ABBV-181.
Expansion Arm C: ABBV-927+ABBV-181ABBV-927Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
Expansion Arm C: ABBV-927+ABBV-181ABBV-181Additional participants with NSCLC will receive IV doses of ABBV-927 and IV doses of ABBV-181.
Primary Outcome Measures
NameTimeMethod
Time to Cmax (Tmax) of ABBV-181Up to 12 weeks after participant's first dose

Time to Cmax (Tmax) of ABBV-181.

Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181Up to 8 weeks

The MTD and the RPTD of ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 will be determined during the dose escalation phase of the study. Once the RPTD has been determined, the dose expansion portion will begin.

Area under the serum concentration-time curve (AUCt) of ABBV-927Up to 12 weeks after participant's first dose

Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-927.

Terminal-Phase Elimination Rate Constant (β) of ABBV-181Up to 12 weeks after participant's first dose

Terminal-phase elimination rate constant (β)of ABBV-181.

Terminal half-life (t1/2) of ABBV-181Up to 4 weeks after participant's first dose

Terminal half-life (t1/2) of ABBV-181.

Area under the serum concentration-time curve (AUCt) of ABBV-181Up to 12 weeks after participant's first dose

Area under the serum concentration-time curve from time zero to the time of last measurable concentration (AUCt) of ABBV-181.

Time to Cmax (Tmax) of ABBV-927Up to 12 weeks after participant's first dose

Time to Cmax (Tmax) of ABBV-927.

Maximum observed serum concentration (Cmax) of ABBV-927Up to 12 weeks after participant's first dose

Maximum observed serum concentration (Cmax) of ABBV-927.

Terminal-Phase Elimination Rate Constant (β) of ABBV-927Up to 12 weeks after participant's first dose

Terminal-phase elimination rate constant (β)of ABBV-927.

Maximum observed serum concentration (Cmax) of ABBV-181Up to 12 weeks after participant's first dose

Maximum observed serum concentration (Cmax) of ABBV-181.

Terminal half-life (t1/2) of ABBV-927Up to 4 weeks after participant's first dose

Terminal half-life (t1/2) of ABBV-927.

Number of Participants with Adverse EventsUp to 30 days after and up to 24-month of treatment period

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Secondary Outcome Measures
NameTimeMethod
Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment)Up to 30 days after and up to 24-month of treatment period

CBR defined as the proportion of subjects with a confirmed partial response (PR), complete response (CR), or stable disease for at least 24 weeks to the treatment.

Progression-free survival (PFS)Up to 30 days after and up to 24-month of treatment period

PFS time is defined as the time from the first dose of ABBV-927 to disease progression or death, whichever occurs first.

Objective response rate (ORR)Up to 30 days after and up to 24-month of treatment period

ORR is defined as the proportion of participants with a confirmed partial or complete response to the treatment.

Duration of objective response (DOR)Up to 30 days after and up to 24-month of treatment period

DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.

Trial Locations

Locations (22)

University Health Network_Princess Margaret Cancer Centre /ID# 200819

🇨🇦

Toronto, Ontario, Canada

The Angeles Clinic and Researc /ID# 156324

🇺🇸

Los Angeles, California, United States

The University of Chicago Medical Center /ID# 155264

🇺🇸

Chicago, Illinois, United States

Massachusetts General Hospital /ID# 155267

🇺🇸

Boston, Massachusetts, United States

Carolina BioOncology Institute /ID# 155265

🇺🇸

Huntersville, North Carolina, United States

Tennessee Oncology-Nashville Centennial /ID# 158654

🇺🇸

Nashville, Tennessee, United States

University of Texas MD Anderson Cancer Center /ID# 155263

🇺🇸

Houston, Texas, United States

Virginia Cancer Specialists - Fairfax /ID# 155266

🇺🇸

Fairfax, Virginia, United States

Peninsula Oncology Centre /ID# 164372

🇦🇺

Frankston, Victoria, Australia

Austin Health /ID# 171189

🇦🇺

Heidelberg, Victoria, Australia

Institut Bergonie /ID# 162665

🇫🇷

Bordeaux, Gironde, France

Duplicate_Institut Regional du Cancer /ID# 163609

🇫🇷

Montpellier CEDEX 5, Herault, France

Centre Leon Berard /ID# 162663

🇫🇷

Lyon CEDEX 08, Rhone, France

Institut Gustave Roussy /ID# 162666

🇫🇷

Villejuif Cedex, Val-de-Marne, France

National Cancer Center Hospital East /ID# 216870

🇯🇵

Kashiwa-shi, Chiba, Japan

National Cancer Center Hospital /ID# 217758

🇯🇵

Chuo-ku, Tokyo, Japan

Seoul National University Hospital /ID# 166291

🇰🇷

Seoul, Seoul Teugbyeolsi, Korea, Republic of

Yonsei University Health System Severance Hospital /ID# 166292

🇰🇷

Seoul, Korea, Republic of

Hospital Universitario Puerta de Hierro - Majadahonda /ID# 200129

🇪🇸

Majadahonda, Madrid, Spain

Hospital Universitario Fundacion Jimenez Diaz /ID# 200128

🇪🇸

Madrid, Spain

Hospital Universitario HM Sanchinarro /ID# 200127

🇪🇸

Madrid, Spain

Hospital Universitario y Politecnico La Fe /ID# 200975

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath